Russian internet firm VK plans share issue after net loss almost triples
Russian internet company VK plans to raise up to 115 billion roubles ($1.36 billion) through an additional share issue to ...
pharmaphorum3d
FDA says yes to MSD’s 21-valent adult pneumococcal jab
The rivalry between Pfizer and MSD in pneumococcal vaccines has dialled up a notch with the FDA approval of MSD’s new shot Capvaxive, the first to be aimed specifically at adults. The 21-valent ...
The Moscow Times on MSN3d
VK Reports Triple Net Loss Despite Record Revenue in 2024
Russian tech giant VK posted a staggering net loss of 94.94 billion rubles ($1.12 billion) in 2024 — nearly three times the ...
pharmaphorum5d
End of the line for MSD's TIGIT, LAG-3 cancer drugs
MSD has decided to abandon the development of its anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, blowing a hole in its immuno-oncology pipeline. The demise of the two ...